Company Overview
Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company. It operates through Beyond Air, Beyond Cancer, and NeuroNos segments. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO to treat viral lung infections, such as viral community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM). In addition, the company develops ultra-high concentration NO (UNO) that is in Phase 1 clinical trial to treat solid tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.
Why Investors Should Care
Net profit has compounded at 13.5% per year over the last five years.
Recent Developments
- Mar 2026 Revenue of $7.68M (+107.3% YoY); net profit $-33.25M.
- Trailing 12 Months Year-on-year growth — revenue +65.5%.
- 5-Year Trend Long-term compounding — profit CAGR 13.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | 65.50% |
Compounded Profit Growth
| 5 Years: | 13.48% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -90.78% |
| 6 Months: | -78.56% |
| 3 Months: | -49.76% |
| 1 Month: | -43.52% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)30.54 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Profit CAGR of 13.5% over 5 years.
CONS
- Trading 92.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | XAIR Beyond Air, Inc. | 5.28 | -0.07 | $3.80M | 0.00% | -106.74% | - | - | 13.48% |
| 2 | LLY Eli Lilly and Company SPX | 1,148.84 | 40.85 | $1.02T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 256.35 | 29.74 | $617.09B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 250.94 | 122.41 | $443.36B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 414.40 | 31.23 | $376.34B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 130.20 | 36.68 | $321.57B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 169.64 | 26.30 | $263.09B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 574.30 | 31.54 | $213.42B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 385.16 | 26.78 | $207.87B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 1.15M | 1.76M | 1.82M | 2.19M | 1.91M |
| Cost of Revenue | - | 1.18M | 1.60M | 2.12M | 1.89M | 1.81M |
| Gross Profit | - | -32.00K | 156.00K | -298.00K | 300.00K | 94.00K |
| Operating Expenses | - | 7.14M | 7.77M | 7.36M | 6.90M | 7.26M |
| Operating Income | - | -7.17M | -7.62M | -7.66M | -6.60M | -7.17M |
| EBITDA | - | -6.54M | -6.60M | -6.70M | -5.65M | -8.21M |
| Interest Expense | - | 580.00K | 548.00K | 639.00K | 1.09M | 1.24M |
| Pretax Income | - | -8.06M | -8.08M | -8.26M | -7.63M | -10.37M |
| Tax Provision | - | 0 | 0 | 0 | 0 | 0 |
| Net Income | - | -8.03M | -7.69M | -7.94M | -7.34M | -10.28M |
| Diluted EPS | - | -36.00 | -30.60 | -25.00 | -17.00 | -15.40 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue | 0 | 1.16M | 3.71M | 7.68M |
| Cost of Revenue | 555.00K | 2.47M | 5.37M | 7.43M |
| Gross Profit | -555.00K | -1.31M | -1.66M | 252.00K |
| Operating Expenses | 51.50M | 61.70M | 42.87M | 29.30M |
| Operating Income | -52.06M | -63.01M | -44.54M | -29.04M |
| EBITDA | -58.20M | -59.03M | -41.89M | -27.17M |
| Interest Expense | 30.00K | 2.91M | 3.02M | 3.52M |
| Pretax Income | -59.40M | -64.30M | -48.48M | -34.33M |
| Tax Provision | 0 | 0 | 0 | 0 |
| Net Income | -55.82M | -60.24M | -46.62M | -33.25M |
| Diluted EPS | -744.00 | -728.00 | -276.00 | -80.20 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 68.75M | 56.96M | 30.06M | 35.38M |
| Current Assets | - | 59.41M | 43.94M | 16.02M | 24.77M |
| Cash & Equivalents | - | 29.16M | 11.38M | 4.67M | 6.74M |
| Inventory | - | 1.13M | 2.13M | 2.42M | 1.41M |
| Receivables | - | 0 | 319.00K | 710.00K | 1.09M |
| Total Liabilities | - | 26.72M | 29.77M | 15.72M | 29.18M |
| Current Liabilities | - | 19.78M | 11.57M | 5.00M | 6.51M |
| Long Term Debt | - | 120.00K | 14.72M | 9.20M | 21.64M |
| Total Debt | - | 3.59M | 17.84M | 11.69M | 23.38M |
| Total Equity | - | 37.91M | 25.05M | 13.58M | 6.13M |
| Shares Outstanding | - | 76.85K | 114.75K | 206.43K | 589.63K |
Cash Flows (Annual)
Figures in USD.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -33.01M | -56.01M | -38.22M | -18.14M |
| Investing Cash Flow | - | -20.59M | -12.23M | 14.90M | -3.67M |
| Financing Cash Flow | - | 2.70M | 43.17M | 16.65M | 29.09M |
| Capital Expenditure | - | -3.88M | -5.75M | -5.88M | -1.02M |
| Free Cash Flow | - | -36.89M | -61.76M | -44.10M | -19.17M |
| Net Change in Cash | - | -50.90M | -25.08M | -6.67M | 7.27M |
Ratios (Annual)
Figures in %.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Gross Margin % | - | -112.8% | -44.9% | 3.3% |
| Operating Margin % | - | -5,436.3% | -1,202.1% | -378.2% |
| Net Margin % | - | -5,197.8% | -1,258.4% | -433.0% |
| ROE % | -147.2% | -240.5% | -343.3% | -542.8% |
| ROCE % | -106.3% | -138.8% | -177.7% | -100.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Balyasny Asset Management LP | 0.16% | 23.21K | $122.42K |
| 2 | Murchinson Ltd. | 0.11% | 16.50K | $87.03K |
| 3 | Geode Capital Management, LLC | 0.06% | 7.97K | $42.05K |
| 4 | Daytona Street Capital LLC | 0.05% | 7.84K | $41.37K |
| 5 | Bleichroeder LP | 0.03% | 4.32K | $22.81K |
| 6 | Commonwealth Equity Services, LLC | 0.02% | 2.37K | $12.50K |
| 7 | Vanguard Capital Management LLC | 0.01% | 1.60K | $8.42K |
| 8 | Vanguard Fiduciary Trust Co | 0.01% | 1.47K | $7.74K |
| 9 | Wealth Effects LLC | 0.01% | 1.42K | $7.48K |
| 10 | Jane Street Group, LLC | 0.01% | 1.38K | $7.26K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for XAIR
XAIR — Frequently Asked Questions
What is the current share price of Beyond Air, Inc. (XAIR)?
As of 2026-08-02 19:16 PDT, Beyond Air, Inc. (XAIR) trades at $5.28 on NasdaqCM. Its 52-week range is $5.16 to $66.20.
What is the market capitalisation of XAIR?
Beyond Air, Inc. (XAIR) has a market capitalisation of $3.80M on NasdaqCM.
What is the P/E ratio of XAIR?
XAIR trades at a trailing price-to-earnings (P/E) ratio of -0.07. The industry average P/E is 27.41. Its price-to-book (P/B) ratio is 0.51.
Is XAIR a good stock to buy?
This page provides a data-driven analysis of Beyond Air, Inc. (XAIR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.